Why did ALEUP.PA stock fall so sharply pre-market?

ALEUP.PA stock fell sharply due to heavy selling and dilution. Volume rose to **371,894** and weighted average shares jumped dramatically, hurting per-share metrics. Weak EPS of **-88.61** and negative cash flow raised immediate investor concern.

What is the Meyka AI forecast for ALEUP.PA stock?

Meyka AI's forecast model projects **€0.27** in one month for ALEUP.PA stock, an implied upside of **31.71%** versus **€0.205**. Forecasts are model-based projections and not guarantees.

What valuation risks should investors watch for ALEUP.PA stock?

Key valuation risks include negative book value, price-to-book **-18.62**, weak current ratio **0.77**, and high operating losses. Continued dilution or funding needs could further depress per-share value.

Where can I find official quotes and recent ALEUP.PA news?

Official live quotes and market coverage are available on Investing.com for Spain and France. See recent updates at [Investing.com Spain](https://es.investing.com/equities/europlasma-sa) and [Investing.com France](https://fr.investing.com/equities/europlasma-sa).

EU Stocks

Pre-market: ALEUP.PA Europlasma S.A. (EURONEXT) down 86.69% 09 Jan 2026: market implications

ByDanny Kontos January 9, 2026

Shares of Europlasma S.A. (ALEUP.PA stock) plunged in pre-market trading on 09 Jan 2026, trading at €0.205 after a one-day drop of -86.69%. Volume is elevated at 371,894 versus an average of 173,161, signalling heavy selling pressure. The move follows continued weak fundamentals, a sharply negative EPS of -88.61, and large share-count growth. Traders in Europe on EURONEXT are pricing elevated operational and dilution risk into the stock ahead of further company updates.